MS patients have a generally increased risk of cardiovascular disease, but there is little data on how different disease modifying treatments may alter this risk in patients treated in clinical practice. In this MEDtalk Thomas Frisell will give you an answer.

In this MEDtalk Nasrin Asgari present an experimental model of neuromyelitis optica spectrum disorder. The model mimicks human disease pathophysiology.

Alemtuzumab treatment in Denmark

Asta Theodorsdottir prsent data from the The Danish Multiple Sclerosis Registry about the demographics of the alemtuzumab-treated population in Denmark; the treatment strategy; the number of cycles and its relation to previous disease modifying treatments (DMTs); and the frequency of switch to other DMTs.

Differentially expressed proteins in MS

In this MEDtalk Tone Berge present new insights into immune-cell processes in MS through evaluate dysregulation af CD4+ and CD8+ cells from MS patients.

Smoking, air pollution and MS

Hear the latest data on the association between smoking and an increased risk of MS. There are several interesting new data.

Adverse events with fatal outcome

Sporadic cases of fatal adverse events have been reported during treatment of multiple sclerosis with alemtuzumab. In this MEDtalk Trygve Holmøy present a study based on European Medicines Agency database of suspected adverse reactions related to medicinal products in the European Economic Area (EudraVigilance), for fatal adverse events associated with treatment with alemtuzumab. Trygve Holmøy and colleagues identified nine cases with a probable and one case with a possible causal relationship between alemtuzumab treatment and a fatal adverse event.

#Tuorein julkaisu

EADV 2020

ECTRIMS 2019 twitterissä